Announcement • Jan 08
Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue Officer Adia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts. Announcement • Oct 22
Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia Med Adia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care. Announcement • Sep 11
Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical Director Adia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs. 
